Mayo Clinic hematologist Rajiv K. Pruthi, M.B.B.S., is an authority on the coagulation-based, molecular and genetic clinical diagnosis of thrombotic disorders, also called coagulation disorders. He is also an expert in managing the bleeding associated with these disorders.
Dr. Pruthi's research focus is on advancing translational science to diagnose these conditions in the laboratory and care for patients with coagulation disorders in clinical settings. His training in molecular biology provides unique insights into the molecular pathology of coagulation disorders and development of clinical assays for diagnosis.
Dr. Pruthi oversees multiple clinical and laboratory operations to drive world-class care at Mayo Clinic, and he mentors trainees and junior faculty to help them achieve their maximum potential and build the hematology workforce of the future.
- Dr. Pruthi and his mentor isolated and characterized the C-terminus of the human vitamin K dependent coagulation protein homologs in different species.
- In Mayo Clinic's comprehensive hemophilia center, Dr. Pruthi led a multiinstitutional, randomized trial of bolus infusion vs. continuous infusion of recombinant activated factor VII in hemophilia patients with inhibitors undergoing major surgery. The trial demonstrated that continuous infusion was not superior to bolus infusions.
- Dr. Pruthi's research team developed and implemented von Willebrand factor multimer analysis gel systems for the optimal diagnosis and classification of von Willebrand disease.
- Dr. Pruthi and colleagues published the largest institutional experience on record of diagnosing patients with autoimmune factor V inhibitors.
- Dr. Pruthi's team published the only validation study for platelet electron microscopy based on Clinical and Laboratory Standards Institute guidelines.
Significance to patient care
Dr. Pruthi's primary research goal is to improve patients' quality of life. His work has contributed to advances in reducing hospitalization, keeping young patients in school and keeping older patients from missing work. He hopes that the field will collectively continue to improve on that.
Areas of potential future study include investigating why some patients have bad joints at earlier ages, which impacts their quality of life. He is also interested in improving research on women with bleeding disorders.
- Co-director, Special Coagulation Laboratory, Mayo Clinic, 2013-present
- Director, Hemophilia Treatment Center, Mayo Clinic, 2000-present
- Co-director, Molecular Hematopathology Laboratory, Mayo Clinic, 1997-present
- Teacher of the Year hematology, Mayo Clinic College of Medicine (now Mayo Clinic College of Medicine and Science), 2005
- Excellence in Teaching Recognition, Mayo Medical School (now Mayo Clinic Alix School of Medicine)
- Karis Award for excellence in patient care, Saint Marys Hospital Sponsorship Board (now the Mayo Clinic Values Council), Mayo Clinic, 2000